David Gardiner
University of Aberdeen(GB)Age UK(GB)
Publications by Year
Research Areas
Hepatitis C virus research, HIV/AIDS drug development and treatment, Chronic Lymphocytic Leukemia Research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection(2014)1,191 cited
- → Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1(2012)607 cited
- → A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection(2013)227 cited
- → Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection(2013)199 cited
- → In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers(2011)185 cited
- → Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders(2013)138 cited
- → Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir(2013)121 cited
- → Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials(2009)94 cited
- → Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide(2008)81 cited
- → 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3(2012)80 cited